Glenmark Pharmaceuticals Inc. to Launch Potassium Phosphates Injection
Filing Summary
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., will launch Potassium Phosphates Injection USP in March 2026. The product will be available in single-dose vials and pharmacy bulk package vials. It is bioequivalent and therapeutically equivalent to the reference drug by Fresenius Kabi. The market for this product achieved annual sales of approximately $51 million according to IQVIA sales data. This launch is part of Glenmark’s strategy to expand its product portfolio in the institutional channel, focusing on providing quality and affordable alternatives.
Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Potassium Phosphates Injection USP. The product will be available in 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL single-dose vials, as well as 150 mmol P / 220 mEq K per 50 mL pharmacy bulk package vials. The distribution is set to begin in March 2026. The injection is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi.
According to IQVIA sales data for the 12-month period ending January 2026, the market for Potassium Phosphates Injection USP achieved annual sales of approximately $51 million. This figure includes both brand and all available therapeutic equivalents. Glenmark’s product is approved for specific indications as listed in its approved label.
The scope of the launch includes the introduction of the injection in various vial sizes to cater to different medical needs. The product is designed to provide an alternative to the existing market offerings, maintaining therapeutic equivalence. The launch aligns with Glenmark’s commitment to expanding its portfolio in the institutional channel, focusing on injectable products.
The market context for this launch is significant, given the existing sales figures and the demand for therapeutic equivalents. Glenmark aims to provide a competitive alternative in the market, leveraging its manufacturing and distribution capabilities. The product’s equivalence to the reference drug positions it as a viable option for healthcare providers.
The timeline for the launch is set for March 2026, with distribution commencing in the same month. Glenmark Pharmaceuticals Inc., USA, will oversee the distribution process. The company is focused on ensuring a seamless introduction of the product into the market, supported by its established infrastructure.
**About Glenmark Pharmaceuticals Ltd.**
Glenmark Pharmaceuticals Ltd. is a global pharmaceutical company focused on innovation and accessibility. The company develops transformative therapies and aims to expand access to high-quality medicines. With multiple manufacturing facilities and R&D centers worldwide, Glenmark delivers a diversified portfolio across various therapeutic areas, including respiratory, dermatology, and oncology.